8-K: INmune Bio Reveals Mixed Phase 2 Alzheimer's Trial Results for XPro, Highlights Subgroup Benefits

INmune Bio announced detailed findings from its Phase 2 MINDFuL trial for XPro in early-stage Alzheimer's disease, revealing the primary endpoint was not met in the overall population but showing consistent beneficial signals in a pre-specified enriched patient subgroup.

Summary

• INmune Bio released additional findings from its Phase 2 MINDFuL trial evaluating XPro, a novel selective soluble tumor necrosis factor inhibitor, for early-stage Alzheimer's disease (AD).
• The primary endpoint was not met in the modified Intention to Treat (mITT) population (n=200) because the placebo-treated group did not show a decline in cognition over the 6-month study period.
• In a pre-specified 'enriched population' (n=100) of patients with amyloid-beta pathology and at least two blood biomarkers of inflammation, XPro1595 demonstrated a beneficial signal consistent across multiple measures, including cognition (EMACC), memory (ISRL), neuropsychiatric symptoms (NPI), and biomarkers (pTau217, GFAP).
• XPro1595 did not show benefit on traditional functional measures (CDR, E-Cog) in the enriched population, but the Goal Attainment Scale (GAS) showed a benefit.
• The trial confirmed XPro's favorable safety profile with no cases of ARIA (amyloid-related imaging abnormalities) and no deaths; the most common treatment-emergent adverse event (TEAE) was Injection Site Reaction (ISR), mostly mild/moderate and resolved.
• The company also provided updates on its other clinical programs: INKmune for metastatic castration-resistance prostate cancer (mCRPC) and CORDStrom for recessive dystrophic epidermolysis bullosa (RDEB).
• INKmune's Phase I/II trial has met its safety endpoint and shown evidence of in-vivo NK cell activation and regression of some tumor lesions by PSMA-PET.
• CORDStrom's Phase 2 trial in RDEB completed, showing beneficial effects on Itch Man Scale, iscorEB clinician score, skin score, and quality of life, with a favorable safety profile and no drug-related serious adverse events.

Sentiment

Score: 7

Explanation: While the primary endpoint for XPro's Alzheimer's trial was not met in the overall population, the company provided a clear explanation and highlighted promising, consistent beneficial signals in a pre-specified enriched patient subgroup. This, combined with positive Phase 2 data for CORDStrom and progress in the INKmune program, suggests overall positive momentum despite the primary endpoint miss, indicating potential for future development and commercialization.

Positives

• XPro1595 showed a consistent beneficial signal across multiple cognitive, neuropsychiatric, and biomarker measures in the 'enriched population' (n=100) of Alzheimer's patients.
• XPro1595 demonstrated a favorable safety profile with no cases of ARIA and no deaths reported in the Phase 2 MINDFuL trial.
• CORDStrom's Phase 2 trial in RDEB showed beneficial effects on itch, wound scores, and quality of life, with a favorable safety profile and no drug-related serious adverse events.
• CORDStrom has received FDA Rare Pediatric Disease and Orphan Drug Designations, qualifying it for a Priority Review Voucher post-FDA approval.
• INKmune's Phase I/II trial for mCRPC has met its safety endpoint and shown evidence of in-vivo NK cell activation and regression of some tumor lesions.

Negatives

• The primary endpoint of the Phase 2 MINDFuL trial for XPro was not met in the overall modified Intention to Treat (mITT) population (n=200).
• The lack of decline in the placebo group within the mITT population made it difficult to assess a treatment effect for XPro in that broader group.
• XPro1595 did not show benefit on traditional functional measures (CDR, E-Cog) in the enriched population.

Risks

• Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved.
• Actual results and the timing of certain events and circumstances may differ materially from forward-looking statements due to risks and uncertainties.
• The company's ability to produce more drug for clinical trials is a risk.
• The availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies, and future product commercialization is uncertain.
• There is no assurance that CORDstrom, XPro1595, and INKmune will be approved by the US Food and Drug Administration (FDA) or any regulatory body, or that any specific results will be achieved.
• The company's business, research, product development, regulatory approval, marketing, and distribution plans and strategies are subject to risks and uncertainties.

Future Outlook

The company plans to validate the 'enriched population' findings for XPro in a fully powered trial and will have an End of Phase 2 meeting with the FDA, EMA, and MHRA in Q3 2025, followed by manuscript submission. For CORDStrom, the next steps involve compiling and filing a Biologics License Application (BLA) in the US and a Marketing Authorization Application (MAA) in the UK/EU in the first half of 2026, with future open-label trials to correlate itch decrease with improved wound healing and demonstrate systemic benefits. For INKmune, the company anticipates completing Phase 2 mCRPC enrollment in Q4 2025 and releasing Phase 2 data in Q1 2026.

Management Comments

• Dr. CJ Barnum, Vice President of CNS Drug Development at INmune Bio, stated, 'The meaningful changes seen in a short trial are very encouraging. We are honored that Dr. Sharon Cohen will present our data at AAIC and look forward to sharing the information more broadly through this video format.'

Industry Context

This announcement relates to the evolving landscape of Alzheimer's disease therapies, particularly those targeting neuroinflammation, a recognized contributor to disease progression. It also touches upon treatments for rare pediatric diseases like RDEB and cancer therapies, specifically for mCRPC, by modulating the innate immune system. The company's approach with XPro, CORDStrom, and INKmune positions it within the broader biotechnology sector focused on precision medicine for chronic inflammation and cancer.

Comparison to Industry Standards

• For Recessive Dystrophic Epidermolysis Bullosa (RDEB), Krystal Biotech's VYJUVEK launched with impressive results, generating approximately $84 million in net revenue in Q3 2024. CORDStrom is positioned as potentially the first systemic therapy for RDEB, with itch benefit as a key differentiating factor, and potential for use as an adjunctive therapy, aiming for a market opportunity estimated at over $1 billion in the US, UK, and EU.

Stakeholder Impact

• Shareholders: Mixed results for XPro's primary endpoint may cause short-term volatility, but positive subgroup data and progress in other programs (CORDStrom, INKmune) offer long-term potential.
• Patients: Potential for new therapeutic options for Alzheimer's disease (XPro), recessive dystrophic epidermolysis bullosa (CORDStrom), and metastatic castration-resistance prostate cancer (INKmune).
• Clinicians: New data on XPro's efficacy in a specific AD subpopulation could guide future treatment strategies; CORDStrom and INKmune show promise for unmet medical needs.
• Regulatory Authorities: The company's engagement with FDA, EMA, and MHRA for XPro and CORDStrom indicates ongoing regulatory pathways for potential approvals.

Next Steps

• Validate the 'enriched population' findings for XPro in a fully powered trial.
• Submit Phase 2 manuscript for XPro.
• Conduct End of Phase 2 meeting with FDA, EMA, MHRA for XPro (Q3 2025).
• File Breakthrough Designation for CORDStrom in RDEB (Q4 2025).
• Complete Phase 2 mCRPC enrollment for INKmune (Q4 2025).
• Release Phase 2 mCRPC data for INKmune (Q1 2026).
• Compile and file Biologics License Application (BLA) in US and Marketing Authorization Application (MAA) in UK/EU for CORDStrom (1H 2026).
• Conduct future open-label trials for CORDStrom to correlate decrease in itch with improved wound healing and demonstrate systemic benefits on extra-cutaneous manifestations.

Key Dates

Recommendation

While the primary endpoint for XPro's Alzheimer's trial was not met in the overall population, the detailed explanation regarding the placebo group's lack of decline and the compelling positive signals observed in the pre-specified 'enriched population' provide a nuanced outlook. The strong safety profile of XPro and the promising Phase 2 results for CORDStrom in RDEB, coupled with its Orphan Drug and Rare Pediatric Disease designations, add significant value. INKmune's progress in mCRPC further diversifies the pipeline. For a seasoned investor, the mixed XPro results warrant a 'hold' to await further validation of the enriched population's findings in a fully powered trial, but the overall pipeline strength and positive safety data suggest long-term potential for those with higher risk tolerance.

Keywords

Alzheimer's disease, XPro, neuroinflammation, Phase 2 trial, MINDFuL trial, soluble TNF inhibitor, biotechnology, clinical-stage, recessive dystrophic epidermolysis bullosa, RDEB, CORDStrom, mesenchymal stromal cells, cancer, metastatic castration-resistance prostate cancer, mCRPC, INKmune, natural killer cells, drug development, biomarkers, clinical trials